- Home
- IMCR vs LU Comparison
IMCR vs LU Comparison
Compare IMCR & LU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMCR | LU |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMCR | LU |
|---|---|---|
| Price | $37.40 | $1.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 1 |
| Target Price | ★ $66.33 | $2.00 |
| AVG Volume (30 Days) | 406.6K | ★ 975.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $8.21 | $22.52 |
| P/E Ratio | $159.17 | ★ N/A |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $1.20 |
| 52 Week High | $40.71 | $4.57 |
Technical Indicators
Market Signals| Indicator | IMCR | LU |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 40.98 |
| Support Level | $35.46 | $1.29 |
| Resistance Level | $37.25 | $1.45 |
| Average True Range (ATR) | 1.27 | 0.08 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 90.54 | 3.50 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.